Preclinical Testing and Animal Model Studies

This contract involves conducting early-stage preclinical research focused on evaluating lead antiviral candidates targeting filoviruses. The work primarily entails using animal models to assess the efficacy, pharmacokinetics, and safety profiles of these promising compounds. The goal is to generate critical data that can inform subsequent development steps and potential therapeutic applications against filovirus infections. Issued as a subcontract under the NAICS code 541611, the opportunity was posted by the Department of Health and Human Services through BARDA, with a submission deadline set for mid-July 2026. Although detailed location and organizational specifics for performance and point of contact are not provided, the contract aligns with public health priorities to address emerging viral threats by advancing antiviral candidate testing in controlled laboratory settings.